Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Accutane/Generics Risk Program Should Include Mandatory Follow-Up Survey

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA advisory committee suggests  enhancements to Roche's SMART program to better prevent pregnancies. The proposal calls for a shared brand/generic system for patient registration.

You may also be interested in...



Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

Enhanced Isotretinoin Risk Management Plan To Commence In Mid-2005

The program will include central registry for patients, prescribers and dispensing pharmacies, an FDA "Talk Paper" says. Celgene licenses patents covering Thalomid STEPS risk management program to isotretinoin manufacturers.

Ventiv Dermatology Sales Force To Promote Ranbaxy’s Isotretinoin

The firms sign multi-year agreement to market Sotret. Ventiv says it has established a specialty dermatology sales force to promote the product.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel